4c for instos, 5c for Big pharma and the rumours were correct, 400% dilution
Radiopharm Theranostics completes A$70 million placement • Radiopharmaceutical industry leader, Lantheus Holdings, Inc., has agreed to make an initial strategic equity investment of A$7.5m at A$0.05 per share, which represents a 47% premium to last closing price of A$0.034 on 19 June 2024 • Two Tranche Placement to raise an additional A$62.5m, taking total amount raised under the placement to A$70.0m • Offer price for shares issued under the balance of the placement of A$0.04 represents an 18% premium to the last closing price • Participation from leading international institutional investors including US specialist healthcare investors • Net proceeds are expected to fully fund the current clinical programs until the end of 2026 • Executive Chair, Paul Hopper, to participate in the placement with A$3.0 million investment, subject to shareholder approval • Option for Lantheus to invest a further A$7.5m within 6 months on the same terms • Lantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and development agreement
CHM Price at posting:
1.8¢ Sentiment: Buy Disclosure: Held
